Insights

Analyst Is Confident on Tesla (TSLA) as Model 3 Cars Can Race Past 5K/Week by Q3:18

Though “skepticism” flies on the Street surrounding Tesla’s Model 3 production challenges, Guggenheim’s Rob Cihra bats for the bulls on Tesla’s odds to hit profitability.

Wedbush Reaffirms Their Sell Rating on Best Buy Co

Wedbush analyst Michael Pachter maintained a Sell rating on Best Buy Co (NYSE: BBY) today and set a price target of $48. The …

Valeant (VRX): Getting Better? Maybe

While Valeant shows signs of a rebound, RBC Capital’s Douglas Miehm remains sidelined.

Valeant (VRX) Hopes Name Change Will Improve Luck, But ‘Full Recovery’ in Dermatology Still Needed, Says BTIG

On back of a solid swing for VRX’s rebounding momentum, BTIG’s Tim Chiang sheds light on Q1 earnings and a forthcoming name change.

Walt Disney (DIS): Does the Lion King Still Rule the Jungle?

GBH Insights’ Daniel Ives believes DIS fundamentals are not the star of the show following FQ2 print; it’s all about the Fox acquisition.

Amedica (AMDA): Did You Feel the Ground Shake, Too?

Maxim’s Jason McCarthy dives into AMDA’s standout silicon nitride asset sidelined only on capital needs.

Celgene (CELG) Gets Two Votes of Confidence from Oppenheimer and Canaccord Following Q1 Update

Oppenheimer’s Leah R. Cann and Canaccord’s John Newman are out with bullish research notes following this biotech giant’s first quarter print.

Achaogen (AKAO) Shares Plummet 26% Following Disappointing AdCom Vote on BSI; Cowen Shares Insights

Cowen’s Chris Shibutani remains confident on AKAO as he angles for plazomicin’s timely approval in cUTI by the end of June.